Skip to main content

Table 2 Association of family history manifestations with HLA-B27 in CBP patients in the SPACE (n = 438) and DESIR cohorts (n = 647)

From: Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts

  SPACE* DESIR**
HLA-B27 + n = 174 HLA-B27– n = 262 OR (95% CI) P value HLA-B27 + n = 376 HLA-B27– n = 270 OR (95% CI) P value
Any PFH 97 87 2.5 (1.7–3.8) <0.001 158 91 1.4 (1.0–2.0) 0.032
AS 65 24 5.9 (3.5–9.9) <0.001 100 27 3.3 (2.1–5.2) <0.001
AAU 23 4 9.8 (3.3–28.9) <0.001 28 1 21.6 (2.9–160.1) 0.003
ReA 5 9 0.8 (0.3–2.5) 0.745 1 5 0.1 (0.01–1.2) 0.075
IBD 12 21 0.9 (0.4–1.8) 0.666 17 15 0.8 (0.4–1.6) 0.551
Psoriasis 34 48 1.1 (0.6–1.8) 0.750 69 60 0.8 (0.5–1.2) 0.225
  1. *Two patients with unknown HLA-B27 status
  2. **One with patient unknown HLA-B27 status
  3. AAU acute anterior uveitis, AS ankylosing spondylitis, CBP chronic back pain, CI confidence interval, HLA-B27 human leukocyte antigen B27, IBD inflammatory bowel disease, OR odds ratio, PFH positive family history (manifestation in first- or second-degree relatives), ReA reactive arthritis